Cellid, Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist

This Cellid, Co., Ltd. Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence maps the organization pipeline, transaction precedent and financial-report signals; Current Awareness tests for fresh event evidence. The output is a practical partnering shortlist with owner, stage, evidence package, IP-risk screen, deal precedent and outreach rationale. The verified organization website is Cellid, Co., Ltd.. Explore the MCP servers used in this report.

Screening date: 3 August 2026. This is a business-development screening memorandum, not legal, patent, medical or investment advice. IP-risk labels are triage flags and not freedom-to-operate conclusions.

Executive BD thesis

Cellid, Co., Ltd. is relevant to the 2026 partnering market because its returned portfolio intersects precision oncology and targeted payload delivery. The organization pipeline query returned 10 linked records and supplied five representative assets for decision screening. The lead record is AdCLD-CoV19(Cellid), with the furthest returned stage shown as Phase 3. The immediate BD question is not whether the company has scientific activity; the MCP evidence confirms that it does. The decision question is where a partner can add territory access, capital, clinical operations, biomarker execution, manufacturing, commercialization infrastructure or combination assets without duplicating the owner’s core capabilities.

Recommendation: ADVANCE TARGETED OUTREACH. Use an asset-specific opening rather than a generic platform pitch. Ask the owner to confirm current rights, active geographies, upcoming milestones, evidence gaps and the internal budget boundary. A credible first proposal should contain one defined asset, one territory or indication, one work package and a staged value-sharing structure.

MCP evidence package: pipeline, owner and stage

The returned pipeline sample is: AdCLD-CoV19(Cellid) (Phase 3; SARS-CoV-2 S protein; COVID-19); BVAC-C (Phase 2; HPV E6 x HPV E7; HPV positive oropharyngeal squamous cell carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck, Uterine Cervical Cancer); BVAC-B (Phase 1; HER2; Breast Cancer, HER2 Positive Stomach Adenocarcinoma, Ovarian Cancer, recurrent gastric cancer, HER2-positive gastric cancer); BVAC-E6E7 (Phase 1; HPV E6 x HPV E7; Squamous cell carcinoma of head and neck metastatic); BVAC-P (Phase 1; ACP3 x PSMA; Glioblastoma, Prostatic Cancer, Renal Cell Carcinoma). The most frequently observed development owner in the returned country-and-status records is Cellid Co., Ltd.. Other owner names surfaced in the evidence include Cellid Co., Ltd.. These names may reflect subsidiaries, co-developers, historical sponsors or local operating entities, so contract-chain verification is required before outreach.

Stage evidence is drawn from the organization pipeline response, not inferred from marketing language. Where an asset has several indication- or country-level statuses, this report uses the furthest returned stage as a screening anchor while preserving the need to verify indication, territory and active-versus-historical status. The sample supports a portfolio-level discussion, but the owner should provide the current data room index, protocol status, regulatory correspondence, manufacturing package and rights schedule before economic terms are discussed.

Partnering shortlist

Deal precedent and financial signal

The transaction screen queried Cellid, Co., Ltd. as licensor and, where no result was returned, as licensee for deals dated from 2021 through the decision date. Returned records are signals for negotiation framing, not complete valuation comparables. A useful precedent must still be normalized for modality, development stage, indication breadth, geography, option mechanics, cost sharing and downstream economics.

The Company & Deal Intelligence deal search returned no company-specific licensor or licensee precedent for the 1 January 2021 to 3 August 2026 screening window. That absence is not proof that no transaction exists; it means valuation should rely on modality-, stage- and territory-matched comparables in the next diligence pass.

For finance, the MCP search tested annual-results, R&D, financing, revenue, cash and strategic-priority language. These signals help determine whether the most credible proposal is an upfront-bearing license, a cost-sharing collaboration, an option-to-license structure, a regional commercialization deal or a milestone-funded development partnership.

• Cellid - Semi-Annual Report(2025.06) — Cellid - Semi-Annual Report(2025.06) ② 전반기 당사의 재무제표는 계속기업으로서 존속할 것이라는 가정을 전제로 작성되었으므로 당사의 자산과 부채가 정상적인 영업활동과정을 통하여 장부금액으로 회수되거나 상환될 수 있다는 가정 하에 회계처리 되었습니다. 이러한 가정에 차질이 발생할 경우 당사의 계속기업에 대한 불확실성은 증가할 수 있습니다. 다만, 당사는 당반기 중 주주배정 후 실권주 일반 공모방식 의 유상증자를 통해 약 350억의 자본을 확충하였으며 이에 자본조달을 기반. MCP reference: financial_report:financial_report_d5c40eb213fa79da4cfb4c1ad15190aa:4e4b216496dd55b81b956d4c5f7ffcea:85.
• Cellid - [Correction of statement]Post-Issuance Report — Cellid - [Correction of statement]Post-Issuance Report Ⅴ. 공시 이행상황 주1) 상기 발행제비용 중 일부는 지급시기에 따라 공모자금 외 자체자금으로 집행할 수 있습니다. 해당 비용에 대한 공 모자금 미사용액은 연구개발비로 지출할 예정입니다. 주2) 상기 자금은확정발행가액을기준으로 산정되었습니다. 당사는 2025년 2분기까지 향후 1년간 19,174백만원의 연구개발비 집행을 예상하고 있으며, 잔여 공모자금 주3) 3,504백만원은 그 이후 연구개발비 목적. MCP reference: financial_report:financial_report_6b05d0d5bc6ae03b5d0c275f25b0c639:c48dd1f82f912a378a5b34d59ea42851:3.
• Cellid - Semi-Annual Report(2023.06) — Cellid - Semi-Annual Report(2023.06) 가. 배당에 관한 사항 당사는 최근 3년간 계속 연구개발에 대한 투자 확대 등에 따라 결손금이 누적되어 배당을 시 행하지 못하고 있습니다. 향후 안정적인 수익창출을 통하여 조속히 배당가능재원을 확보할 예정이며, 배당을 주주에 대한 이익반환의 기본 형태로 보고 적극적인 주주 환원 정책을 펴 나가겠습니다. 당사는 상법상 배당가능재원 확보시, 회사 정관 규정에 의거하여 이익 규모 및 미래성장을 위한 투자재원 확보, 기업의 재무구조 건전성. MCP reference: financial_report:financial_report_d5c40eb213fa79da4cfb4c1ad15190aa:855593fcacec9fc1ef4d799f13d421ac:80.

Current Awareness check

The Current Awareness query tested clinical-trial, licensing, partnership, regulatory-milestone and financing language for Cellid, Co., Ltd.. No company-specific news chunk was returned in this scan. This should be treated as a workflow flag, not evidence that nothing changed. Before contacting management, rerun Current Awareness, review the organization website and confirm the latest trial, regulatory, financing and corporate-development events. The outreach email should explicitly ask whether any milestone, financing process or exclusivity discussion changes the availability of the shortlisted assets.

IP and evidence-risk screen

The principal IP risks are ownership-chain ambiguity, composition or sequence claims, target and method-of-use overlap, formulation or delivery claims, manufacturing know-how, university or inventor obligations, and territory-specific patent coverage. For advanced assets, regulatory exclusivity, licensed background IP, combination dependencies and freedom to operate may be as important as the core patent family. For early assets, enablement, claim breadth, inventorship and access to translational assays are central. No outreach should imply an FTO conclusion; request a family-level patent schedule, prosecution status, encumbrances, third-party licenses and any dispute or opposition history.

Evidence risk should be separated from IP risk. Confirm the current protocol, endpoints, enrollment status, data cut, safety profile, CMC readiness, assay transferability and regulator feedback. A partner should be able to trace each value claim to a dated source package. If the owner cannot supply a clean rights map and evidence index, structure diligence and payments in stages rather than pricing the opportunity as fully de-risked.

Outreach rationale and proposed next step

Open with the lead asset, AdCLD-CoV19(Cellid), and the returned Phase 3 status. State the specific capability being offered: regional development, trial execution, biomarker work, manufacturing scale-up, combination access, specialist commercialization or structured financing. Then ask five questions: who controls each territory; which indication and formulation are in scope; what milestone occurs next; what evidence package can be shared under CDA; and what transaction structure the board is prepared to consider.

A strong first meeting should produce a rights map, milestone calendar, evidence-room index, IP responsibility matrix and comparable-deal set. The recommended commercial path is a staged process: confidential validation, asset-and-territory prioritization, non-binding structure, focused diligence and then economics. This protects both sides from broad, low-conversion discussions and keeps the proposal tied to an executable work package.

BD decision

Advance targeted outreach, subject to rights and evidence confirmation. The MCP pipeline response provides a defensible reason to engage; the transaction and finance searches define what is known and what remains missing; the Current Awareness result creates a clear pre-contact refresh step. The next owner should be the business-development lead responsible for precision oncology and targeted payload delivery, supported by clinical, regulatory, CMC and IP colleagues for the lead asset.

PatSnap Life Sciences MCP servers turn fragmented pipeline, deal, finance and event checks into a repeatable BD screening workflow. Re-run this scan before any decision meeting to refresh stages, transactions and recent signals. Explore PatSnap MCP servers and build the next opportunity scan.